Editing Interferon beta-1a (section)

===Economics===
In the United States, {{as of|2015|lc=yes}}, the cost is between US$1,284 and US$1,386 per 30 mcg vial.<ref>{{cite news|vauthors=Langreth R|title=Decoding Big Pharma's Secret Drug Pricing Practices|url=https://www.bloomberg.com/graphics/2016-drug-prices/|access-date=15 July 2016|publisher=Bloomberg|date=June 29, 2016|archive-date=13 July 2016|archive-url=https://web.archive.org/web/20160713133019/http://www.bloomberg.com/graphics/2016-drug-prices/|url-status=live}}</ref> As of 2020, the National Average Drug Acquisition Cost (NADAC) in the United States for Avonex was $6,872.94 for a 30 mcg kit.<ref>{{Cite web|url=https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2020-02-12/2ghv-q5xv|title=NADAC as of 2020-02-12 | work = Centers for Medicare and Medicaid Services|language=en|access-date=2020-02-18|archive-date=2020-02-18|archive-url=https://web.archive.org/web/20200218171241/https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2020-02-12/2ghv-q5xv|url-status=dead}}</ref>

Avonex and Rebif are on the top ten best-selling multiple sclerosis drugs of 2013.<ref>{{Cite web|url=https://www.fiercepharma.com/special-report/top-10-best-selling-multiple-sclerosis-drugs-of-2013|title=The top 10 best-selling multiple sclerosis drugs of 2013|website=FiercePharma|date=9 September 2014|access-date=8 August 2021|archive-date=26 February 2024|archive-url=https://web.archive.org/web/20240226115050/https://www.fiercepharma.com/special-report/top-10-best-selling-multiple-sclerosis-drugs-of-2013|url-status=live}}</ref>

It is an example of a [[specialty drugs|specialty drug]] that would only be available through a [[specialty pharmacy]]. This is because it requires a refrigerated chain of distribution and costs $17,000 a year.<ref name="ncbi_2013">{{cite journal | vauthors = Gleason PP, Alexander GC, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, Shah ND | title = Health plan utilization and costs of specialty drugs within 4 chronic conditions | journal = Journal of Managed Care Pharmacy | volume = 19 | issue = 7 | pages = 542–548 | date = September 2013 | pmid = 23964615 | doi = 10.18553/jmcp.2013.19.7.542 | pmc = 10437312 }}</ref>

{| class="wikitable"
|-
! No. !! 2013 Global Sales !! [[International Nonproprietary Name|INN]] !! Brand names !! Companies
|-
| 1 || $4.33 billion || [[Glatiramer acetate]] || Copaxone || Teva
|-
| 2 || $3.00 billion || Interferon beta 1a || Avonex || Biogen Idec
|-
| 3 || $2.51 billion || Interferon beta 1a || Rebif || Merck KGaA
|-
| 4 || $1.93 billion || [[Fingolimod]] || Gilenya || Novartis
|-
| 5 || $1.41 billion || [[Natalizumab]] || Tysabri || Biogen Idec
|-
| 6 || $1.38 billion || [[Interferon beta 1b]] || Betaseron/Betaferon || Bayer HealthCare
|-
| 7 || $876 million || [[Dimethyl fumarate]] || Tecfidera || Biogen Idec
|-
| 8 || $303 million || [[4-Aminopyridine]] || Ampyra || [[Acorda Therapeutics]]
|-
| 9 || $250 million || [[Adrenocorticotropic hormone]] || H.P. Acthar Gel || Questcor Pharmaceuticals
|-
| 10 || $221 million || [[Teriflunomide]] || Aubagio || Sanofi
|}